Clinical Trials Browser

Recurrence × Nivolumab × 1 year × Clear all

Neoplasms, Recurrence

NCT03686124 2026-04-13

ACTengine

Phase 1/2 Recruiting

375 enrolled

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

68 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

57 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03233152 2025-11-21

GlitIpNi

Phase 1/2 Active not recruiting

110 enrolled

CNS

Glioblastoma, Recurrence

NCT03557359 2025-11-03

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Phase 2 Completed

35 enrolled 9 charts

CNS

Glioma, Recurrence

NCT02628574 2025-08-03

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1 Completed

109 enrolled

Neoplasm Metastasis, Recurrence

Clinical Trials

HESTIA